Anitha Thomas
BC Cancer Agency
10 Papers
13 Citations
Anitha Thomas is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Liposome & Chemistry. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines.
Anna K. Blakney,Paul F. McKay,Kai Hu,Karnyart Samnuan,Nikita Jain,Andrew F. Brown,Anitha Thomas,Paul Rogers,Krunal Polra,Hadijatou Sallah,Jonathan Yeow,Yunqing Zhu,Molly M. Stevens,Andrew Geall,Robin J. Shattock +14 more
TL;DR: In this article, the role of biomaterials in vaccine immunogenicity is investigated, including lipid nanoparticles (LNP), polyplexes and cationic nanoemulsions, and the results indicate that delivery systems and routes of administration may fulfill different delivery niches within the field of saRNA genetic medicines.
80
Development of a liposomal nanoparticle formulation of 5-Fluorouracil for parenteral administration: Formulation design, pharmacokinetics and efficacy
Anitha Thomas,Anita I. Kapanen,Jennifer I Hare,Euan Ramsay,Katarina Edwards,Göran Karlsson,Marcel B. Bally +6 more
TL;DR: The therapeutic effects of the LNP 5-FU formulation, as determined in a HT-29 subcutaneous colorectal cancer model where treatment was given QDx5, was greater than that which could be achieved with free 5-fu when compared at equivalent doses.
77
Microfluidic Production and Application of Lipid Nanoparticles for Nucleic Acid Transfection.
Anitha Thomas,Shyam M. Garg,Rebecca Anne Grace De Souza,Eric Ouellet,Grace Tharmarajah,Dave Reichert,Mina Ordobadi,Shell Ip,Euan Ramsay +8 more
TL;DR: The methodology for preparing LNPs loaded with siRNA, mRNA or plasmids using a commercially available microfluidic instrument and an accompanying transfection kit are described and are seamlessly scalable to quantities appropriate for in vivo models and development of nucleic acid therapeutics.
14
Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model
Nidhi Jyotsana,Amit Sharma,Anuhar Chaturvedi,Colin Walsh,Anitha Thomas,Michaela Scherr,Matthias Eder,Karin Battmer,Florian Kuchenbauer,Sajti Laszlo,Annette Barchanski,Kerstin Goerlich,Robert Lindner,Fatih Noyan,Suehs.Kurt Wolfram,Denis Grote-Koska,Korbinian Brand,Hans-Peter Vornlocher,Arnold Ganser,Euan Ramsay,Pieter R. Cullis,Michael Heuser +21 more
TL;DR: The BCR-ABL dependent K562-CML xenotransplantation model is established and employed as a proof of principle to validate LNP mediated siRNA functional delivery in vivo and shows a highly efficient and non-toxic delivery in vitro and in vivo.
2
Patent
Compositions for Transfecting Resistant Cell Types
Anitha Thomas,Brown Andrew William,De Souza Rebecca Anne Grace,Fernandez Tara L +3 more
- 07 Nov 2019
TL;DR: In this article, a reagent composition for delivery nucleic acid therapeutics to cells is provided, which includes ionizable lipid, structural lipid, and a stabilizing agent which improves the transfection efficiency of nucleic acids, and leaves transfected cells viable.
1